Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: a health system perspective on thrombolytic therapy for acute myocardial infarction.
Lewandowski
C A
CA
Department of Emergency Medicine, Pharmacy and Therapeutics Committee, Henry Ford Health System, Detroit, MI 48202-2689, USA.
Kahler
J
J
D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D019033:Delivery of Health Care, Integrated; D019049:Developed Countries; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010606:Pharmacy and Therapeutics Committee; D015912:Thrombolytic Therapy / Q000191:economics*
D005343:Fibrinolytic Agents